Carregant...
Results of a Phase II Trial of Brentuximab Vedotin for CD30(+) Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
PURPOSE: Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30(+) receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30(+) cutaneous T-cell lymphomas. PATIENTS AND METHODS: Forty-eight patients with CD30(+) ly...
Guardat en:
| Publicat a: | J Clin Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4737859/ https://ncbi.nlm.nih.gov/pubmed/26261247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.3787 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|